BridgeBio Pharma (BBIO) News Today → The only financial event in 2024 that matters (From Porter & Company) (Ad) Free BBIO Stock Alerts $28.01 -0.84 (-2.91%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31 at 5:50 AM | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Earns "Buy" Rating from HC WainwrightMay 30 at 8:22 AM | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $43.00 price target on shares of BridgeBio Pharma in a research report on Thursday.May 30 at 5:17 AM | marketbeat.comNorges Bank Makes New $46.84 Million Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Norges Bank acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,160,342 shares of the company's stock, valued at appMay 30 at 1:54 AM | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Rating Reiterated by Cantor FitzgeraldMay 29 at 6:39 PM | finance.yahoo.comAdditional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)May 29 at 4:01 PM | globenewswire.comAdditional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma's Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)May 29 at 3:08 AM | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Price Target Lowered to $47.00 at UBS GroupMay 28, 2024 | marketbeat.comBridgeBio Pharma's (BBIO) Overweight Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and set a $70.00 price target on shares of BridgeBio Pharma in a research report on Tuesday.May 28, 2024 | markets.businessinsider.comBuy Rating Affirmed on BridgeBio Pharma Amid Promising ATTRibute-CM Study ResultsMay 28, 2024 | marketbeat.comUBS Group Cuts BridgeBio Pharma (NASDAQ:BBIO) Price Target to $47.00UBS Group decreased their price target on BridgeBio Pharma from $51.00 to $47.00 and set a "buy" rating on the stock in a report on Tuesday.May 27, 2024 | investorplace.com7 Biotech Stocks to Put on Your Breakthrough RadarMay 26, 2024 | marketbeat.comUBS Group AG Has $39.79 Million Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)UBS Group AG raised its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 545.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 985,510 shares of the company's stock after purchasing an additional 832,940 shares during the period.May 26, 2024 | americanbankingnews.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 26, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of "Moderate Buy" by AnalystsBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eleven analysts that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one hasMay 24, 2024 | globenewswire.comBridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA MeetingMay 23, 2024 | marketbeat.comAssenagon Asset Management S.A. Decreases Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Assenagon Asset Management S.A. cut its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 81.0% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,995 shares of the company's stock after selling 29,739 shaMay 23, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for BridgeBio Pharma, Inc. (NASDAQ:BBIO) Decreased by HC WainwrightMay 22, 2024 | finance.yahoo.comParty Time: Brokers Just Made Major Increases To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Earnings ForecastsMay 22, 2024 | marketbeat.comHC Wainwright Brokers Cut Earnings Estimates for BridgeBio Pharma, Inc. (NASDAQ:BBIO)BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Equities researchers at HC Wainwright decreased their Q2 2024 earnings estimates for BridgeBio Pharma in a research report issued to clients and investors on Monday, May 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company wiMay 20, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Price Target Cut to $43.00HC Wainwright lowered their price objective on shares of BridgeBio Pharma from $47.00 to $43.00 and set a "buy" rating for the company in a research report on Monday.May 19, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. boosted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 6.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 1,123,220 shares of the company's stock after acquiring an additional 66,94May 17, 2024 | marketbeat.comPrincipal Financial Group Inc. Purchases 197,818 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Principal Financial Group Inc. increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 26.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 943,484 shares of the company's stock afMay 16, 2024 | markets.businessinsider.comPromising Clinical Data Bolsters Buy Rating for BridgeBio PharmaMay 16, 2024 | benzinga.comBridgeBio Pharma's Options: A Look at What the Big Money is ThinkingMay 16, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Up 7.7% in AprilBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) was the target of a large increase in short interest in April. As of April 30th, there was short interest totalling 16,230,000 shares, an increase of 7.7% from the April 15th total of 15,070,000 shares. Based on an average daily volume of 1,670,000 shares, the short-interest ratio is currently 9.7 days. Approximately 11.5% of the shares of the stock are short sold.May 15, 2024 | globenewswire.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 14, 2024 | markets.businessinsider.comBuy Rating on BridgeBio Pharma: Enhanced Market Prospects from Acoramidis Efficacy and Mortality BenefitMay 14, 2024 | marketbeat.comEvercore ISI Begins Coverage on BridgeBio Pharma (NASDAQ:BBIO)Evercore ISI assumed coverage on BridgeBio Pharma in a report on Tuesday. They issued an "outperform" rating and a $50.00 target price on the stock.May 14, 2024 | globenewswire.comBridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024May 13, 2024 | globenewswire.comBridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study PopulationMay 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for BridgeBio Pharma on Strong Clinical Data for AcoramidisMay 3, 2024 | finance.yahoo.comBridgeBio Pharma First Quarter 2024 Earnings: Beats ExpectationsMay 3, 2024 | markets.businessinsider.comBuy Rating Affirmed: BridgeBio Pharma’s Growth Trajectory Bolstered by Strong Pipeline and Strategic InitiativesMay 2, 2024 | sfgate.comBridgeBio Pharma: Q1 Earnings SnapshotMay 2, 2024 | globenewswire.comBridgeBio Pharma Reports First Quarter 2024 Financial Results and Business UpdateMay 1, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Up 5.5% in AprilBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 15,070,000 shares, a growth of 5.5% from the March 31st total of 14,280,000 shares. Based on an average daily volume of 1,690,000 shares, the short-interest ratio is presently 8.9 days. Currently, 10.9% of the company's stock are sold short.April 30, 2024 | markets.businessinsider.comMaintaining Buy Rating on BridgeBio Pharma: Undervalued Potential of Acoramidis Amid Market UnderperformanceApril 26, 2024 | marketbeat.comabrdn plc Invests $11.51 Million in BridgeBio Pharma, Inc. (NASDAQ:BBIO)abrdn plc acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 284,993 shares of the company's stock, valued at approximately $11,50April 22, 2024 | marketbeat.comDuality Advisers LP Buys 31,036 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Duality Advisers LP raised its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 63.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 80,192 shares of the company's stock after purchasing an adApril 21, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Holdings Lowered by Vontobel Holding Ltd.Vontobel Holding Ltd. trimmed its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 53.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,811 shares of the company's stock after sApril 20, 2024 | uk.investing.comBridgeBio Pharma Inc (BBIO)April 16, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Up 6.5% in MarchBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 14,280,000 shares, a growth of 6.5% from the March 15th total of 13,410,000 shares. Based on an average daily trading volume, of 1,730,000 shares, the days-to-cover ratio is presently 8.3 days. Approximately 10.3% of the shares of the stock are sold short.April 12, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Trading Down 5.7%BridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 5.7%April 11, 2024 | finance.yahoo.comBridgeBio Pharma, Inc. (BBIO)April 10, 2024 | globenewswire.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 10, 2024 | globenewswire.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for BridgeBio Pharma on Acoramidis’ Positive ATTR-CM Trial OutcomesApril 7, 2024 | globenewswire.comBridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)April 6, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) have been given an average recommendation of "Moderate Buy" by the twelve analysts that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and ten have issued a buy recommendatMarch 28, 2024 | marketbeat.comVanguard Group Inc. Trims Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Vanguard Group Inc. reduced its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 3.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,275,981 shares of the company's stock after s Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Crypto That You Don’t Own… Yet (Ad)There’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening. Click here for all the details… BBIO Media Mentions By Week BBIO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BBIO News Sentiment▼0.440.78▲Average Medical News Sentiment BBIO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BBIO Articles This Week▼185▲BBIO Articles Average Week Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Amicus Therapeutics News Schrödinger News Allakos News Alnylam Pharmaceuticals News Teva Pharmaceutical Industries News Genmab A/S News Royalty Pharma News BeiGene News BioMarin Pharmaceutical News Viatris News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BBIO) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
